Under AAAResearchReports.com Microscope: Amarin Corp. PLC, Elan Corp. PLC, Seattle Genetics Inc., and Cubist Pharma Inc.

LONDON, October 15, 2013 /PRNewswire/ --

On Monday, October 14, 2013, the S&P 500 ended the day at 1,710.14, up 0.41%; the Dow Jones Industrial Average closed at 15,301.26, up 0.42%; and the NASDAQ Composite finished at 3,815.28, up 0.62%. Shares of companies in the healthcare sector mostly ended on a higher note, as the broader market posted gains. The major movers in the sector included Amarin Corporation PLC (NASDAQ: AMRN), Elan Corporation PLC (NYSE: ELN), Seattle Genetics Inc. (NASDAQ: SGEN), and Cubist Pharmaceuticals Inc. (NASDAQ: CBST). AAAResearchReports.com has released full comprehensive research on AMRN, ELN, SGEN, and CBST. These free technical analyses can be downloaded by signing up at:

http://www.AAAResearchReports.com/register/    

Shares in Amarin Corp. PLC declined on Monday, extending the losses from the previous trading session. The company's shares ended the day at $5.01, which is 1.57% lower than the previous day's price of $5.09. The company's shares vacillated between $4.50 and $5.25 during the trading session. A total of 16.89 million shares were traded, which is significantly above the daily average volume of 5.22 million. Amarin Corp. PLC's stock has fallen by 4.84% in the previous three months, underperforming the S&P 500 which has advanced 1.78% during the same period. Additionally, the company's shares are trading below their 50-day and 200-day moving averages of $6.29 and $7.02, respectively. A free technical analysis on AMRN available by signing up at:

http://www.AAAResearchReports.com/AMRN101513.pdf  

On Monday, Elan Corp. PLC's stock edged higher, after hitting a new 52-week high of $16.13. The company's shares closed the day at $16.12, up 0.69% from the previous day's price of $16.01. A total of 8.06 million shares were traded, which is less than the daily average volume of 9.89 million. Elan Corp. PLC's shares have gained 4.34% in the last one month and 13.84% in the previous three months, outperforming the S&P 500 which has advanced 1.31% and 1.78% during the respective periods. Furthermore, the company's stock is currently trading above its 50-day and 200-day moving averages of $15.50 and $12.91, respectively. Register today and access free research on ELN at:

http://www.AAAResearchReports.com/ELN101513.pdf  

On Monday, Seattle Genetics Inc.'s stock closed at $39.75, up 0.08% from the previous day's closing price of $39.72. The company's shares fluctuated between $38.68 and $39.80 during the trading session. A total of 1.03 million shares were traded, which is more than the daily average volume of 0.81 million. The company's shares have gained 0.38% in the previous three trading sessions and 4.28% in the last three months, compared to a gain of 3.24% and 1.78% in the S&P 500 during the respective periods. Moreover, Seattle Genetics Inc.'s stock is trading above its 200-day moving average of $35.71. The free report on SGEN can be downloaded by signing up now at:

http://www.AAAResearchReports.com/SGEN101513.pdf  

Cubist Pharmaceuticals Inc.'s stock posted gains on Monday, extending the gains from the previous trading session. The company's shares traded between $64.58 and $66.56 before ending the day 0.85% higher at $66.50. A total of 0.92 million shares were traded, which is below the daily average volume of 1.16 million. The company's shares have gained 4.48% in the previous three trading sessions and 23.33% in the last three months, outperforming the S&P 500 which has advanced 3.24% and 1.78% during the respective periods. Further, Cubist Pharmaceuticals Inc.'s stock is trading near its 52-week high of $68.00 and above its 50-day and 200-day moving averages of $63.65 and $51.84, respectively. A free report on CBST can be accessed by registering at:

http://www.AAAResearchReports.com/CBST101513.pdf  

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE AAA Research Reports